January 5, 2016
This webinar explored the international science policy landscape for biotechnology and ideas for building gene drive research and technology assessment capacity. The webinar was an information-gathering meeting for the committee in which the speakers are invited to provide input to the committee.
International Biotechnology Policy and Research Capacity Building – Genya Dana, US State Department
Dr. Genya Dana is Senior Science Policy Officer at U.S. Department of State. Dr. Dana is an advocate for science, technology, and innovation as a key component of sustainable development and poverty alleviation. She specializes in providing advice on synthetic biology and international policy actions to the United States government and other stakeholders. Dr. Dana is the lead negotiator and expert on synthetic biology in the Convention on Biological Diversity and other international policy fora. Due to her efforts, Dr. Dana received the 2015 Superior Honor Award for formulating the first United States government position on synthetic biology for use in international fora. She fosters partnerships between companies, universities, non-profits and governments to increase scientific and technological capacities in Africa. Dr. Dana also increases the US State Department’s technical capacity through the management of four science policy fellowship programs.
Building Capacity for Technology Assessment – Clifford Goodman, The Lewin Group
Dr. Goodman is a Senior Vice President at The Lewin Group, a health care policy consulting firm based in Falls, Church, Virginia. Dr. Goodman has 30 years of experience in such areas as health technology assessment (HTA), evidence-based health care, comparative effectiveness research, health economics, and studies pertaining to health care innovation, regulation, and payment. He directs studies and projects for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; health care provider institutions; and professional, industry, and patient advocacy groups. His recent work has involved such areas as oncology, cardiovascular disease, diabetes, blood disorders, obesity, end-stage renal disease, HIV/AIDS, follow-on biologics, diagnostic testing, pharmacogenomics, personalized medicine, and organ donation and transplantation. Dr. Goodman is an internationally recognized health policy issues moderator and facilitator of expert panels, health industry advisory boards, workshops, and focus groups, having conducted more than 170 such events over the last five years. He is a special consultant on HTA to the China National Health Development and Research Center, Ministry of Health (National Health and Family Planning Commission), People’s Republic of China. Dr. Goodman served as Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC, 2009-12) for the US Centers for Medicare and Medicaid Services (CMS). He served as President of the professional society, Health Technology Assessment International (HTAi, 2011-13), and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He received a PhD from The Wharton School of the University of Pennsylvania, a Master of Science from The Georgia Institute of Technology, and a Bachelor of Arts from Cornell University.